Hemosol is an integrated biopharmaceutical company developing innovative life sustaining therapies, used initially for the treatment of acute anemia. The Company's immediate focus is on the development and successful commercialization of HEMOLINK™ [hemoglobin raffimer]. Hemosol also is furthering the development of its multi-product pipeline based on two platform technologies--protein bioconjugation and cell expansion.